Enterprise Value
-47.72M
Cash
147.4M
Avg Qtr Burn
-25.19M
Short % of Float
2.91%
Insider Ownership
2.19%
Institutional Own.
62.86%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Fosgonimeton (ATH-1017) Details Alzheimer's disease | Phase 2/3 Data readout | |
Fosgonimeton (ATH-1017) Details Parkinson's disease, Dementia | Phase 2 Update | |
ATH-1105 Details Amyotrophic lateral sclerosis | Phase 1 Initiation |